Help Keep MSDF Alive!
Do you find MSDF invaluable? If so, please help us continue by making a tax-deductible donation NOW.
If you’re reading this message, it’s because you’re one of the 16,000 unique monthly visitors to the Multiple Sclerosis Discovery Forum. You know that MSDF is a source of accurate, unbiased news and information—the only such source focused exclusively on multiple sclerosis and related disorders.
I’m the executive editor of MSDF, and I’m proud of what we’ve created: a unique combination of news and background articles written by professional science journalists, viewpoints from thought leaders and subject matter experts, and technical resources that enable sharing and analysis of information and open discussion among MS stakeholders in academia, industry, and the clinic. All content on the site is provided on an open-access basis to the entire MS community.
We provide this content freely, but of course it costs real money to create it. Without real money we can’t hire science journalists with experience writing about neuroscience and immunology for a professional audience. Without real money we can’t hire the data scientists who produce our data visualizations. Without real money we can’t cover the important scientific conferences that focus on multiple sclerosis.
That’s why I’m asking you today for your financial support, without which we cannot survive. While MSDF has received generous contributions from a number of sources, including the National Multiple Sclerosis Society, EMD Serono, and Genzyme, we need a whole lot more from individuals such as yourself.
MSDF is part of the Accelerated Cure Project for Multiple Sclerosis, a 501(c)3 charity focused on innovation in MS research. Your contribution to MSDF is tax deductible. Please help support us today.
And if you have any questions about any of this, please contact me directly at email@example.com.
Key open questions
- How will MSDF keep providing independent news coverage of MS research?
- How much can you contribute to our goal of communicating MS research news in a way that builds bridges among different disciplines and may open new routes toward significant clinical advances?